NasdaqGS - Nasdaq Real Time Price • USD
Pyxis Oncology, Inc. (PYXS)
As of 10:17 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
82,196.0000
82,196.0000
123,481.0000
69,717.0000
12,894.0000
Operating Income
-82,196.0000
-82,196.0000
-123,481.0000
-69,717.0000
-12,894.0000
Net Non Operating Interest Income Expense
6,630.0000
6,630.0000
2,764.0000
23.0000
66.0000
Other Income Expense
1,776.0000
1,776.0000
--
-6,281.0000
--
Pretax Income
-73,790.0000
-73,790.0000
-120,717.0000
-75,975.0000
-12,828.0000
Net Income Common Stockholders
-73,790.0000
-73,790.0000
-120,717.0000
-75,975.0000
-12,828.0000
Diluted NI Available to Com Stockholders
-73,790.0000
-73,790.0000
-120,717.0000
-75,975.0000
-12,828.0000
Basic EPS
-1.85
--
-3.65
-8.95
-0.58
Diluted EPS
-1.85
--
-3.65
-8.95
-0.58
Basic Average Shares
39,904.6030
--
33,033.0810
8,493.2730
22,126.5130
Diluted Average Shares
39,904.6030
--
33,033.0810
8,493.2730
22,126.5130
Total Operating Income as Reported
-82,196.0000
-82,196.0000
-123,481.0000
-69,717.0000
-12,894.0000
Total Expenses
82,196.0000
82,196.0000
123,481.0000
69,717.0000
12,894.0000
Net Income from Continuing & Discontinued Operation
-73,790.0000
-73,790.0000
-120,717.0000
-75,975.0000
-12,828.0000
Normalized Income
-73,790.0000
-73,790.0000
-120,717.0000
-69,744.0000
-12,828.0000
Interest Income
6,630.0000
6,630.0000
2,764.0000
23.0000
66.0000
Net Interest Income
6,630.0000
6,630.0000
2,764.0000
23.0000
66.0000
EBIT
-82,196.0000
-82,196.0000
-123,481.0000
-69,717.0000
-12,894.0000
EBITDA
-80,269.0000
-80,269.0000
-122,772.0000
-69,070.0000
-12,425.0000
Reconciled Depreciation
1,927.0000
1,927.0000
709.0000
647.0000
469.0000
Net Income from Continuing Operation Net Minority Interest
-73,790.0000
-73,790.0000
-120,717.0000
-75,975.0000
-12,828.0000
Total Unusual Items Excluding Goodwill
--
--
--
-6,231.0000
--
Total Unusual Items
--
--
--
-6,231.0000
--
Normalized EBITDA
-80,269.0000
-80,269.0000
-122,772.0000
-62,839.0000
-12,425.0000
12/31/2020 - 10/8/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ELEV Elevation Oncology, Inc.
3.7350
-3.74%
BCAB BioAtla, Inc.
2.3100
-1.70%
LBPH Longboard Pharmaceuticals, Inc.
19.43
-1.64%
IGMS IGM Biosciences, Inc.
7.05
-11.43%
TARA Protara Therapeutics, Inc.
2.8650
+1.59%
ACRV Acrivon Therapeutics, Inc.
9.40
-1.05%
MRUS Merus N.V.
42.10
+0.31%
CGEM Cullinan Therapeutics, Inc.
18.83
-0.32%
BCYC Bicycle Therapeutics plc
22.38
-1.28%
ETNB 89bio, Inc.
8.16
-4.90%